Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

British Journal of Haematology

Volumn 165, Issue 3, 2014, Pages 375-381

  Tuscano, Joseph M ^a,b   Dutia, Mrinal ^a   Chee, Karen ^c   Brunson, Ann ^a   Reed Pease, Christine ^a   Abedi, Mehrdad ^a   Welborn, Jeanna ^a   O'Donnell, Robert T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Veteran's Administration Northern California Health Care System   (United States)

^c California Cancer Care   (United States)

Author keywords

Fc receptor polymorphisms; Lenalidomide; Lymphoma; Rituximab

Indexed keywords

LENALIDOMIDE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FCGR3A GENE; FEMALE; FOLLICULAR LYMPHOMA; GENE; GENETIC POLYMORPHISM; HUMAN; HYPONATREMIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UNITED STATES; VERY ELDERLY;

FC RECEPTOR POLYMORPHISMS; LENALIDOMIDE; LYMPHOMA; RITUXIMAB;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, IGG; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84898467895     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12755     Document Type: Article

References (32)

1. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I. & Solal-Céligny, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 15, 1110-1117.
2. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
3. Cheson, B.D., Horning, S.J., Coiffer, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
4. Davis, T.A., Maloney, D.G., Gillo-Lopez, A.J., White, C.A., Wilaims, M.E., Weiner, G.J., Dowden, S. & Levy, R. (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clinical Cancer Research, 6, 2644-2652.
5. Dutia, M., De Roock, I., Reed-Pease, C., O'Donnell, R.A. & Tuscano, J.M. (2010) Lenalidomide overcomes FCRG3A-mediated resistance to rituximab in patients with relapsed/refractory indolent non-Hodgkin's lymphoma: a correlative analysis of a phase 2 study. Blood (ASH Annual Meeting Abstracts), 116, 367.
6. Fowler, N.H., McLaughlin, P., Hagemeister, F.B., Kwak, L.W., Fanale, M.A., Neelapu, S.S., Fayad, L., Orlowski, R.Z., Wang, M. & Samaniego, F. (2010) Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 28, 15s, abstr 8036.
7. Friedberg, J.W., Neuberg, D., Gribben, J.G., Fisher, D.C., Canning, C., Koval, M., Poor, C.M., Green, L.M., Daley, J., Soiffer, R., Ritz, J. & Freedman, A.S. (2002) Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. British Journal of Haematology, 117, 828-834.
8. Gaidarova, S., Corral, L.G., Glezer, E., Schafer, P.H. & Lopez-Girona, A. (2009a) Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing. Blood (ASH Annual Meeting Abstracts), 114, 1687.
9. Gaidarova, S., Li, J.W., Corral, L.G., Glezer, E., Schafer, P.H., Xie, W., Lopez-Girona, A., Cheson, B.D. & Bennett, B. (2009b) Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases. Blood (ASH Annual Meeting Abstracts), 114, 3441.
10. Gandhi, A.K., Kang, J., Capone, L., Shafarenko, M. & Schafer, P.H. (2009) Anti-proliferative and apoptotic activity of lenalidomide in combination with rituximab in follicular lymphoma: an in vitro and ex vivo analysis in follicular lymphoma cells. Blood (ASH Annual Meeting Abstracts), 114, 3723.
11. Griggs, J. & Zinkewich-Peotti, K. (2009) The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. British Journal of Cancer, 101, 1807-1812.
12. Hernandez-Ilizaliturri, F.J., Reddy, N., Holkova, B., Ottman, E. & Czuczman, M.S. (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clinical Cancer Research, 11, 5984-5992.
13. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
14. Kaufmann, H., Raderer, M., Wöhrer, S., Püspök, A., Bankier, A., Zielinski, C., Chott, A. & Drach, J. (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood, 104, 2269-2271.
15. Lapalombella, R., Yu, B., Triantafillou, G., Liu, Q., Butchar, J.P., Lozanski, G., Ramanunni, A., Smith, L.L., Blum, W., Andritsos, L., Wang, D.S., Lehman, A., Chen, C.S., Johnson, A.J., Marcucci, G., Lee, R.J., Lee, L.J., Tridandapani, S., Muthusamy, N. & Byrd, J.C. (2008) Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 112, 5180-5189.
16. Leonard, J.P., Schuster, S.J., Emmanouilides, C., Couture, F., Teoh, N., Wegener, W.A., Coleman, M. & Goldenberg, D.M. (2001) Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer, 113, 2714-2723.
17. Leonard, J.P., Gregory, S.A., Maloney, D.G., Vose, J.M., Younes, A. & Zelenetz, A.D. (2008) Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 6, 437-445.
18. Leonard, JP., Sin-Ho, J., Johnson, J.L., Bartlett, N., Blum, K.A. & Cheson, B.D. (2012) CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 30, 8000.
19. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology, 26, 4579-4586.
20. van Oers, M.H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R.E., Wolf, M., van t Veer, M., Vranovsky, A., Holte, H., Hagenbeek, A. & van der Reijden, B.A. (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. Journal of Clinical Oncology, 28, 2853-2858.
21. Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J.C. & Gribben, J.G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. The Journal of Clinical Investigation, 118, 2427-2437.
22. Ramsay, A.G., Clear, A.J., Kelly, G., Fatah, R., Matthews, J., Macdougall, F., Lister, T.A., Lee, A.M., Calaminici, M. & Gribben, J.G. (2009) Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood, 114, 4713-4720.
23. Reddy, N., Hernandez-Ilizaliturri, F.J., Deeb, G., Roth, M., Vaughn, M., Knight, J., Wallace, P. & Czuczman, M.S. (2008) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British Journal of Haematology, 140, 36-45.
24. Sacchi, S., Pozzi, S., Cesaretti, M., Marcheselli, L., Liardo, E.V., Buda, G., Lazzaro, A., Baldini, L., Di Raimondo, F., Musto, P., Zaccaria, A., Specchia, G., Vitolo, U., Magagnoli, M., Fattori, P.P., Tosi, P. & Carella, A.M. (2012) Results of a phase II study of lenalidomide in combination witrh rituximab for the treatment of indolent non-follicular non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts), 120, 1645.
25. Samaniego, F., Hagemeister, F., Mclaughlin, P., Kwak, L.W., Romaguera, J., Fanale, M.A., Neelapau, S.S., Fayad, L., Orlowski, R.Z., Wang, M., Lacerte, L. & Fowler, N.H. (2011) High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 29, 8030.
26. Simon, R. (1989) Optimal two-stage design for phase II clinica trials. Controlled Clinical Trials, 10, 1-10.
27. Weng, W.K. & Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 3940-3947.
28. Witzig, T.E., Wiernik, P.H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J.B. & Vose, J.M. (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 5404-5409.
29. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P. & Bartlett, J.B. (2008) Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clinical Cancer Research, 14, 4650-4657.
30. Zhang, L.H., Schafer, P.H., Muller, G., Stirling, D. & Bartlett, B. (2008) Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression [abstract]. Blood (ASH Annual Meeting Abstracts), 112, 2612.
31. Zhang, L.H., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J.B., Yi, Q. & Wang, M. (2009) Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. American Journal of Hematology, 84, 553-559.
32. Zinzani, P.L., Pellegrini, C., Gandolfi, L., Stefoni, V., Quirini, F., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S. & Baccarani, M. (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B cell lymphoma: a phase 2 trial. Clinical Lymphoma, Myeloma and Leukemia, 11, 462-466.